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Abstract
Approximately 13% of the pediatric population suffer from atopic dermatitis (AD) or eczema
(Silverberg & Simpson, 2014). Eczema is a complex and costly managed disease. There is a
need to improve caregiver knowledge and to maintain and control exacerbations as national
prevalence increases in the United States. Literature supports utilization of a written Eczema
Action Plan (EAP) to improve caregiver self-efficacy of eczema management. An evidencebased practice project was conducted in a primary care pediatric practice implementing a written
EAP for mild to severely diagnosed patients ranging from 4 months to 17 years of age. The
practice intervention included providing each caregiver with an individualized written EAP
developed by the American Academy of Dermatology (AAD), an eczema patient education
handout by The Society for Pediatric Dermatology, and a list of over-the-counter products
endorsed by the National Eczema Association. Thirty caregivers were recruited for this pilot and
22 participants completed the project. The validated Patient Oriented Eczema Measurement for
children (POEM) and the Parental Self-Efficacy Care Index (PASECI) tools were completed by
caregivers pre-intervention and again between 6- and 8-weeks post-intervention. Eczema
severity decreased by approximately 65% and caregiver self-efficacy increased with an average
score of 8.11/10 utilizing the PASECI. A written EAP is easily adaptable in the primary care
setting closing communication barriers between caregiver and provider. Utilization of a written
EAP establishes best care practice congruent with the American Academy of Pediatrics (AAP)
clinical guidelines. Potential benefits include reduction in follow-up visits, treatment costs,
improvement in referral identification, and increased caregiver and patient satisfaction.
Keywords: eczema action plan, childhood eczema, caregiver self-efficacy, POEM,
PASECI
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Background and Evidence for Clinical Problem
Eczema primarily affects children. Eighty-five percent of children diagnosed with eczema
have an onset of the disease before 5 years of age (Tollefson, Bruckner, & Dermatology, 2014).
The condition can range in severity from mild to severe forms causing pruritus, pain, and an
increased risk for infections. Managing eczema is a challenge for parents because skincare is
complex and must include specific treatment for flare-ups and long-term maintenance (Shi,
Shivani, Lee, Armstrong, & Lio, 2013). Lack of adherence to complex treatment regimens is a
common cause of treatment failure in many long-term conditions in children including eczema,
asthma and diabetes (Waldecker, Malpass, King, & Ridd, 2013). Ineffective management of
childhood eczema stems from lack of parental knowledge and self-efficacy regarding the
condition, skincare maintenance, and treatment of acute exacerbations. For the care in
management of AD for children, the AAD insists the use of written action plans as an
educational intervention to reinforce parental education and improve AD severity (Sidbury,
Bergman, Copper, Silverman, & Berger, 2014).
Eczema can negatively affect the quality of life for patients and their family physically
and emotionally. An informal systematic review found itching and scratching affected the
quality of life in children the most in addition to lack of sleep, pain, and restrictions in physical
and social activities. Family members were affected by symptoms of itching and scratching due
to lack of sleep and feelings of helpless emotions seeing their children suffer. A systematic
review concluded that when AD severity increases, quality of life decreases as well. Studies
revealed generalized eczema is responsible for the second greatest impact affecting quality of life
following cerebral palsy (Drucker et al., 2017). The impact of eczema on quality of life of the

3

MANAGING CHILDHOOD ATOPIC DERMATITIS
family is not limited to the United States. In broader spectrum, the results of a current crosssectional study of 110 children in Malaysia shows AD negatively affects the quality of life for
patients as well as their family members evidenced by the Dermatitis Family Impact score
(Ghani, Noor, Muhamad, & Ismail, 2013).
Childhood Eczema in the United States and California
The prevalence of childhood eczema is increasing in the United States. A most recent
study analyzed data from the 2007 National Survey of Children’s Health. A national sample of
92,642 children ages 0 to17 years revealed 12.9% had been diagnosed with childhood eczema
(Silverberg & Simpson, 2014) as opposed to 10.7% in a previous study conducted 3 years prior
(Shaw, Currie, Koudelka, & Simpson, 2011). This increase indicates a need for quality
improvement in the management of eczema by primary care providers and caregivers. Of the
12.9% of diagnosed patients, 67% had mild disease, 26% have moderate disease, and 7% have a
severe form of eczema (Silverberg & Simpson, 2014). Furthermore, the rate of severe
childhood eczema in the state of California is 5.9% (Silverberg & Simpson, 2014).
Expenditures for AD add to the burden for families. The average cost to manage AD one
month prior to seeing a provider is $274 in the United States (Filanovsky et al., 2016). The
national estimated annual costs to manage eczema is $5.297 billion dollars (Drucker et al., 2017).
Improved management of mild to moderate eczema in pediatric primary care can potentially
prevent disease progression and improve long-term outcomes.
Childhood Eczema Management in a Pediatric Primary Care Clinic
Eczema is commonly treated by providers in pediatric primary care with topical
emollients and corticosteroids. In some cases, the condition is poorly managed by caregivers and
the severity of eczema worsens causing physical discomfort and emotional stress to the child and
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family. Successful management of this condition requires parents to have a knowledge of
eczema, triggers, a prescribed skincare regimen, and how to manage flare-ups. Common practice
to educate parents primarily includes verbal instruction without the use of a written plan. Verbal
instructions can be vague leaving parents feeling inadequate to care for their child’s eczema.
The AAP supports the use of an EAP to provide comprehensive education for parents managing
the symptoms of childhood eczema. Although clinical guidelines have been published by the
AAP to implement EAPs, variability exists in clinical practices (Tollefson & Bruckner, 2014).
Gaps in parental education have led to different expected outcomes between parents and
providers. A qualitative study at the University of Bristol determined the challenges of
managing eczema included a lack of support and information provided to parents resulting in
differing views about its causes and management. Some parents were looking for a cure due to a
root cause such as an allergy. Primary care providers viewed eczema as a chronic condition
recommending emollients to prevent exacerbations (Powell, Roux, Banks, & Ridd, 2018).
Additionally, another qualitative study demonstrated many families were unaware of the reason
behind why emollients were even suggested (Santer et al., 2013).
Poorly managed eczema was reported by the physician and observed by the Doctor of
Nursing (DNP) candidate at the clinical site of this pilot study. Due to a lack of an electronic
medical records (EMR) system, it was difficult to track the prevalence of eczema in the practice.
The DNP candidate blindly reviewed 100 paper health records to determine the prevalence of
eczema in the practice. Forty-one percent had documentation of an eczema diagnosis during
various time periods of care indicating a strong need for caregiver intervention.
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Proposed Evidence-Based Solutions
A literary search was conducted using PubMed, CINAHL Plus, Health and Psychosocial
Instruments, and Google Scholar. Key words included eczema action plan, pediatric atopic
dermatitis, self-management of eczema, parental education, parental self-efficacy, and eczema
severity index. The search yielded 3592 articles and was narrowed to 32 pertinent articles
mostly published less than 5 years ago. Of the 32 articles reviewed, 26 articles were used in this
final pilot project.
The utilization of a written EAP in conjunction with verbal instruction increases parental
confidence level when managing daily skincare of mild to severe symptoms of eczema. A recent
randomized controlled trial included parents of 88 children diagnosed with AD ranging in age
from 1 month to 12 years found the use of an EAP over a span of 3 months demonstrated
significant improvement in parental confidence through quality of life measures. Improvement
was demonstrated in domains that included, “I feel certain about what to do when my child’s
skin is getting worse,” (P=.003), “know names of creams to use on my child’s skin,” (P=.016),
and “feel helpless about my child’s skin condition,” (P=.034) (Gilliam, Madden, Sendowski,
Mioduszewski, & Duderstadt, 2016).
Another randomized controlled trial included a combination of 37 AD patients and
caregivers of children less than 18 years of age showing how an EAP combined with verbal
instruction significantly improved multiple areas of eczema management. Some of the domains
demonstrating improvement included daily treatment plan (P<.01), adjust treatment based on AD
severity (P<.001), remission recognition (P<.001), and comfort with treatment plan (P<.01) (Shi
et al., 2013). Recent evidence validated EAPs are useful and can be applied to primary care
practice.
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The AAP provided a sample EAP for the management of AD within their most recent
atopic dermatitis guidelines (Tollefson et al., 2014). It includes a step-by-step process of daily
skincare maintenance, application of anti-inflammatory medications, itch control, and
recognition of exacerbations. There are currently no guidelines that standardizes EAP format or
content. The International Consensus Conference on AD II (ICCAD II) suggested EAPs follow
specific criteria that includes written instructions remain with the patient, has a step-wise
treatment approach based on severity of symptoms, and content should be validated by patients
and caregivers (Sauder, McEvoy, & Ramien, 2016).
Use of a 3-step EAP format was preferred by parents and may increase confidence in the
knowledge of skincare management according to a qualitative study from the University of
Bristol. Forty-one participants including healthcare professionals from multiple disciplines,
parents, and stakeholders provided input to create an eczema written action plan (EWAP) for
children. They designed an EWAP based on clear instructions presented in a step-by-step
process with color and pictures to engage children and aid in communication and comprehension
for parents. Generalized information about eczema including the condition itself, triggers, tips
for moisturizing, flare-up recognition, and additional links to resources was included in the final
EWAP design at the request of the participants (Powell et al., 2018). The EWAP format and
content closely mimics criteria set forth by the ICCAD II, however it has not been validated in
clinical practice.
Establishing a clear understanding of eczema helps parents and providers share the same
treatment goals. In the University of Bristol study, general practitioners identified conflicting
treatment goals between providers and parents as a barrier to successfully treating and managing
eczema. The participants of the study, including parents and general practitioners, preferred
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receiving and distributing general eczema information including the rationale for using
emollients (Powell et al., 2018). In addition, previous research showed when practitioners
established a strong relationship with parents by providing a clear explanation of eczema,
adherence to treatment was more likely (Santer et al., 2013). It is important to provide parents
with generalized eczema information to create a better understanding of the condition, the course
of treatment, and provider expectations.
Providers who take time to explain treatment plans to parents increase parental
comprehension of skin management. In order to close the communication gap between providers
and caregivers of pediatric patients, practitioners need to be willing to take the time to explain
treatment plans. This includes highlighting the disease process and explaining proper medication
administration. Written EAPs should be explained carefully in order to engage caregivers in
various aspects of skincare management. This principle of shared decision making can result in
improved long-term outcomes (Levy, 2013).
There is currently no standardized written action plan design that has been clinically
tested for effectiveness with the exception of a few studies where EAPs were independently
created. Currently a multi-disciplinary group from the Children’s Hospital of Eastern Ontario in
Ottawa, Canada are in the process of developing and clinically testing a written action plan
(Innes-Leroux, 2016). Currently no validated action plan has been disseminated. The AAD and
The Society for Pediatric Dermatology created a pediatric EAP and a patient education handout
of general eczema information respectively (“How will I know what to do to control the
eczema?,” 2018; “Patient Handouts,” 2018.). These resources are available for public use
without cost. The formats are congruent with that of the EWAP and the ICCAD II criteria and
therefore were utilized in this pilot study.
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Description of EBP Project
This pilot project was conducted in a private pediatric clinic with one physician, the DNP
candidate, three nursing assistants, and an office manager. Patients diagnosed with eczema were
identified by the physician and DNP candidate during well-check and ill visits. Caregiver
participation was voluntary. Prior to implementation, parents completed a demographics
questionnaire (see Appendix A), the validated POEM (see Appendix B) designed for children to
rate eczema severity, and the validated PASECI (see Appendix C) to measure caregiver selfconfidence (Charman, Venn, & Williams, 2004; Ersser et al., 2015). The DNP candidate then
implemented an individualized written EAP designed by the AAD and individualized it to each
patient based on the physician’s orders (see Appendix D). In addition, caregivers received an
eczema patient education handout published by the Pediatric Society of Dermatology (see
Appendix E) and a list of National Eczema Association approved over-the-counter products
including moisturizers and cleansers (see Appendix F). Caregiver comprehension of the EAP
was measured immediately post intervention using a Likert-like survey question (see Appendix
G).
The POEM and PASECI questionnaire were completed again between 6- and 9-weeks
post EAP intervention via Google Forms. The average response time was 7.14 weeks. A $20 gift
card incentive was offered to each participant for completion of the questionnaires after a 6-week
timeframe (see Appendix H). A systematic review concluded the use of moisturizers in patients
who had mild to moderate eczema effectively treated eczema within a 6 week to 6 month
timeframe justifying the follow-up time for this pilot project (Becker & Rensberry, 2018).
Documentation of EAP implementation and the date of issue to caregivers was completed
in each patient record by the DNP candidate. The EAP will remain an important part of the
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patients’ course of eczema care and management. The primary care provider will be able to
obtain an understanding of caregiver eczema health literacy and guide the decision-making
process to modify the EAP or conduct a referral to dermatology in the event eczema is not
controlled in the future.
Measurements
The POEM designed for children was utilized to obtain the extent of eczema severity as
reported by the caregiver of the child. The POEM consists of seven questions of equal weight.
All seven questions ask the caregiver to describe how often eczema symptoms are experienced
from zero days to every day. POEM scores were calculated by adding up points for all seven
questions. Each question was worth zero to four points dependent on how often symptoms
presented within the last week for a maximum score of 28. The outcome of the total score
helped patients and clinicians identify the severity of eczema from clear or almost clear to very
severe eczema. The POEM is validated and suitable for use in outpatient clinic settings
(Charman et al., 2004). It is copyrighted by the University of Nottingham and free for clinicians
to use. The English version of the POEM was utilized in this project.
The POEM instrument has been utilized in current studies. In 2015, a randomized
clinical trial compared the effectiveness of direct verses online access for eczema follow-up care
for pediatric and adult patients. Additionally, it was used in this trial to assess disease severity.
Results indicated direct and online access to care were equivalent in clinical outcomes
(Armstrong et al., 2015). In 2017, a randomized control trial used the POEM and demonstrated
children in ambulatory care with mild eczema did not clinically benefit from oral and topical
antibiotics in addition to topical emollients and corticosteroids (Francis et al., 2017).
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The PASECI was utilized to examine caregiver self-efficacy in eczema management. It
is validated and reliable with high consistency in all domains (Cronbach’s  > 0.87) (Ersser et
al., 2015). The instrument is organized into four sections. Sections include parental confidence
measurements in managing medication, managing symptoms, communicating with health care
professionals, and managing personal challenges. There are 29 total questions and confidence
levels are measured using a Likert-like scale from 0 (cannot do at all) to 10 (highly certain can
do). For the purposes of this project, only caregiver ability to manage eczema and symptoms
were examined. The seven parental self-efficacy category measurements included caregiver
ability to apply moisturizers, chose appropriate moisturizers, avoid triggers, chose appropriate
medication, manage symptoms, recognize infection and properly use topical steroids. Currently,
only an English and Korean version of the PASECI have been validated (Lee, Son, Kim, Han, &
Noh, 2016). The PASECI instrument has not been found in recent eczema management studies.
Anticipated Project Outcomes
Three short-term goals were established for this project. The first goal was to obtain
parent comprehension of the implemented EAP with a reported average score of 8 of 10 using a
Likert-like survey question. A score of 0 equated to no understanding and score of 10 equated to
full understanding. Parental comprehension was rated immediately after the implementation of
the EAP to ensure successful parental education. The second goal was for parents to report
reduced eczema severity post intervention by an average of 5 points utilizing the validated
POEM tool. The POEM tool was completed by parents at the initial encounter and again at 6
weeks. The third goal was for parents to score an average of 8 of 10 for self-efficacy using the
PASECI post EAP intervention. Similarly, this tool was completed by parents at the initial
encounter and again at 6 weeks.
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Anticipated Project Impact
The overall goal of this pilot project was to provide important instruction and education
to parents of children with AD in hopes to reduce eczema severity. The EAP and general
information about eczema are important tools to help parents efficiently and confidently manage
their child’s skincare with this regressive condition. Managing eczema can be complicated.
Increasing communication between the provider and parent may promote better outcomes for
treatment, adherence of treatment regimens and improve quality of life for children who are
affected by eczema. The results of this project may have a potential impact on future research
and projects allowing an evidence-based intervention such as the written EAP to become
standardized nationally and worldwide.
PICOT Question
P: In a primary care clinic, pediatric patients ages 4 months to 17 years of age diagnosed with
mild to moderate atopic dermatitis also known as eczema
I: Provide parent/caregiver education using a written Eczema Action Plan (EAP) in addition to
verbal teaching
C: Compared to standard verbal teaching of eczema management
O: Result in decreased severity of child eczema symptoms and increased parental self-efficacy
T: Within 6 weeks-10 weeks
EPB Model
The Iowa Model was selected as the evidence-based practice model for this pilot project.
It is a constant challenge for nurses to provide the highest quality care that is measurable and
evidence-based. If care is not evidence-based, a potential for patient harm may increase (Doody
& Doody, 2011). The Iowa Model is an excellent framework to help engage the stakeholder and
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pilot the written EAP systematically, then evaluate and adjust intervention accordingly. The
Iowa Model is knowledge focused as is the intervention and helped to individualize evidencebased practice into this clinical setting. Validity of evidence was variable. The Iowa Model
served as guide in the introduction, development and evaluation of evidence-based practice. The
model was used to evaluate if the EAP was appropriate for adoption by analysis of its structure,
process, and outcome data in order to deliver the best clinical care. Results will be disseminated
and if sustainable, the Iowa Model can continuously guide a written EAP into multidisciplinary
healthcare settings.
Project Process Plan
A letter of support was obtained by the sole provider of the practice approving use of
collected data and dissemination on April 20, 2018 (see Appendix I). University of San Diego
(USD) faculty approval was obtained April 24, 2018 (see Appendix J). The USD Institutional
Review Board approved an exempt status on April 27, 2018 (see Appendix K).

Data collection

began on April 20, 2018 and the EAP was implemented by the DNP candidate. A total of 30
voluntary participants were enrolled in this pilot project. The DNP candidate sent out electronic
copies of the written EAP via text to participants between 1-2 weeks post EAP implementation
and offered to answer any questions caregivers had regarding the EAP. At about 6-7 weeks post
intervention, participants were contacted via text message to complete the POEM and PASECI
questionnaires. Of the 30 participants, 22 completed the post-intervention POEM and PASECI
via Google Forms. Twenty-dollar gift cards to Walmart were mailed individually to participants
who completed post intervention measurements. Eight participants were lost to follow-up for
unknown reasons. Data collection concluded on August 1, 2018. Data analysis was conducted
between August 1, 2018 to August 22, 2018.
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Dissemination
A significant component of completing an evidence-based project is to share the results.
The dissemination of project findings was presented to key stakeholders including the sole
physician and the entire staff on January 30, 2019. A successful poster presentation was
conducted at the clinical site. The poster included background, evidence for the clinical problem,
purpose of the project, project plan, results of data analysis, conclusions, and implications for
clinical practice.
A second presentation took place on campus at the USD Project Presentation Day on
February 28, 2019. A PowerPoint presentation was created to present the pilot project and its
findings to fellow students and faculty at the Hahn School of Nursing. An exchange of questions
and answers prompted interest and ideas of clinical implications and inspiration to upcoming and
experienced practitioners.
A third presentation took place at a national health conference in the form of a poster
presentation. This project was selected by The California Association for Nurse Practitioners
42nd Annual Educational Conference that took place March 14-17, 2019 in San Diego,
California. The results of this pilot project were shared on a broader statewide and national level
to healthcare providers who showed interest in integrating EAPs into their clinical practice.
Sustainability
It is important to consider how use of a written EAP will remain sustainable in this
clinical practice. The dissemination of results may motivate the provider and staff to continue
utilization in order to provide best practice and positive long-term outcomes for patients and their
families. The physician and the clinic nurse could become champions to continue
implementation. Copies of written EAPs can be stored near other patient education handouts for
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visibility and accessibility. This practice is implementing an electronic medical record system in
the near future. An electronic prompt could be created as a reminder for the physician to use
EAPs as an important tool to manage eczema.
Additionally, satisfaction surveys could be distributed among participants of this study
one year later that may reveal a higher patient satisfaction. A good rapport was established
between the physician and the DNP candidate throughout this project. It is possible the DNP
student continue and encourage sustainability with the practice every 6 months for the first-year
post EBP project via casual face-to-face discussion or by text messaging to find out if any
challenges arise with the EAP and provide suggestions for improvement. All these elements
combined will help successfully sustain the EAP long-term greater than 12 months.
Results
Caregivers reported a 9.8 comprehension level immediately following receipt of the EAP.
Analysis of the data revealed improvement in eczema severity and caregiver self-efficacy.
Eczema severity decreased from an average of 7.33 POEM points (mild to moderate severity) to
an average of 2.55 points (clear to mild severity) post-intervention (see Figures 1 and 2). Fortyfive and a half percent of the sample had no change in severity, 55% showed decreased change,
and 4.5% had an increase in severity (see Figure 3).
Caregiver self-efficacy improved from an average of 5.51 PASECI points to an average
of 8.11 points post-intervention (see Figure 4). There was improvement in 100% of seven
measured PASECI categories. Post-intervention, caregivers reported most confidence increase in
how well they were able to appropriately use steroids with a 33.3% improvement, how well they
were able to recognize infection with a 32.9% improvement, and how well they were able to
manage eczema symptoms with a 27.5% improvement (see Figure 5). There was a significant
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correlation between the pre and post PASECI scores; 19.36% of a change in the post PASECI
could be explained by the pre PASECI score (r = .441, p = .040), however statistical significance
was underpowered by the sample size.
Ninety percent of caregivers reported they had never utilized an EAP prior to this project.
The majority of caregivers were 64% mothers and 27% fathers between the ages of 26 to 35
years of age. The primary languages reported were 44% English, 27% Vietnamese, and 60%
percent of caregivers worked full-time. Eighty percent of children were 5 years of age and
younger with an equal distribution of male and females. Fifty-three percent children were
reported Hispanic and 23% were Asian. Thirty-three percent had a family history of seasonal
allergies, and 20% had a family history of asthma. Forty percent had been diagnosed with
eczema less than six months while 40% had been diagnosed for greater than a year. Refer to
Tables 1-10 for a more detailed description of the project demographics.
Implications for Clinical Practice
The results of this pilot project support the beneficial use of written EAPs in primary care
as presented by previous evidence. Formatted and individualized EAPs are comprehensible and
improve caregiver confidence and self-efficacy resulting in decreased severity of childhood
eczema symptoms. Demographic analysis and limitations of this project prove availability of
translated EAPs and educational handouts may have increased impact if offered in a caregiver’s
primary language. As caregiver confidence levels increase, they feel more equipped to manage
and care for childhood atopic dermatitis. Lifelong maintenance including proper use of
medications and avoidance of environmental triggers requires a standard approach clinicians can
easily utilize in practice. Dissemination of this small project may influence future evidencebased projects and research of a larger scale in order to produce potential statistically significant
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data and validation of a written EAP. Future studies and projects may expand EAP utilization
beyond pediatric primary care to other clinical or non-clinical environments. Morover, family
quality of life could be evaluated as well as long-term physiologic and psychologic outcomes of
eczema patients. Further research and evidence may substantiate the use of a written EAP
standardizing design and method to better equip caregivers in the lifelong maintenance and
control of childhood atopic dermatitis.
Cost-benefit Analysis
Utilization of a written EAP in primary care is cost-effective. A financial key benefit
resulting from this project was treatment cost savings for families. The total costs for this
project was approximately $620 including $40 of purchased materials, $440 of participant
incentives, and $140 for paper copies to create an EAP packet for each parent. The average out
of pocket expenses is approximately $274 per month for families who seek multiple over the
counter treatments before seeing a provider (Filanovsky et al., 2016). For patients who are not
typically covered by health insurance, effective treatments include moisturizers and prescribed
steroid creams. This cost is approximately $100 per month (“How Much Does Eczema
Treatment Cost?,” 2018). Each patient would be able to save about $174 per month with correct
and effective treatment as directed by use of the EAP. For this project of 30 initial participants,
$174 x 30 patients = $5220 eczema treatment costs per month. Potential patient cost avoidance
benefit was approximately $8.42 for every $1.00 spent on this project. This was approximately a
742% return on investment with use of an EAP in comparison to no EAP.
Non-financial key benefits from this project included congruence of AAP clinical
guidelines and best evidence-based clinical practice. A reduction in eczema severity may
potentially decrease the risk for infection, emergency department visits, and hospital admissions.
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Additionally, the practice may benefit from EAP implementation with an increase in service
availability for higher acuity conditions. If eczema severity is unchanged or worsens,
documented use of the EAP may help the provider improve identification for dermatology
referrals. Furthermore, caregivers may recognize the quality of individualized medical services
received for their child generating positivity and loyalty to the practice.
Limitations
This project included a recruitment of 30 voluntary participants, however due to
contraints of the project, the potential quantity of contributors was limited due to different factors
including language, small private practice, and timeline limitations. Of 30 participants, 22
completed the project. Inclusion requirements to participate in the project were ability to speak,
read, and write in English. No translated versions of the EAP, patient education handouts, or
instruments were offered. Data analysis showed English was the primary language for
approximately 44% of the sample followed dominantly by Vietnamese and Spanish. Although
many of the participants met inclusion criteria, some caregivers may have been unable to
participate in follow-up asssessments due to English language barriers. Time contraits of this
project also contributed to the small size of the sample and was restricted due to academic time
limitations. Although monetary incentive was offered to participants to complete the follow-up
surveys, it is unclear if the reward was deemed valuable to them. Inability to use a smart phone
to text and use Google Forms, change in contact information, forgetfulness, personal reason or
choice to not participate in follow-up may have been additional factors explaining reasons for not
completing the post survey.
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Conclusion
Two of the three anticipated project outcomes were met. The caregiver EAP
comprehension goal was met with 9.8 of 10. Eczema severity decreased by 4.78 out of 5 POEM
points post intervention and indicates a successful outcome. The caregiver self-confidence goal
was met with an average of 8.11 of 10. Atopic dermatitis affects an estimated 30% of the United
States population with the majority including the pediatric population (“Eczema (Atopic
Dermatitis) | NIH: National Institute of Allergy and Infectious Diseases,” 2018.). There is
currently no standardized tools used to manage eczema in the pediatric primary care setting.
Literature has proven comprehensive caregiver education through use of a written EAP
decreased symptom severity and improved caregiver self-efficacy. Implementing EAPs in the
primary pediatric care setting is a feasible practice which may successfully increase caregiver
knowledge in managing eczema and reduce clinical symptoms.

19

MANAGING CHILDHOOD ATOPIC DERMATITIS
References
Armstrong, A. W., Johnson, M. A., Lin, S., Maverakis, E., Fazel, N., & Liu, F.-T. (2015). PatientCentered, Direct-Access Online Care for Management of Atopic Dermatitis: A
Randomized Clinical Trial. JAMA Dermatology, 151(2), 154–160.
https://doi.org/10.1001/jamadermatol.2014.2299
Becker, A., & Rensberry, M. (2018). Effectiveness of Moisturizers in the Treatment of Patients
with Eczema. American Family Physician, 97(1), 18–19.
Charman, C. R., Venn, A. J., & Williams, H. C. (2004). The patient-oriented eczema measure:
development and initial validation of a new tool for measuring atopic eczema severity
from the patients’ perspective. Archives of Dermatology, 140(12), 1513–1519.
https://doi.org/10.1001/archderm.140.12.1513
Doody, C. M., & Doody, O. (2011). Introducing evidence into nursing practice: using the IOWA
model. British Journal of Nursing, 20(11), 661–664.
https://doi.org/10.12968/bjon.2011.20.11.661
Drucker, A. M., Wang, A. R., Li, W.-Q., Sevetson, E., Block, J. K., & Qureshi, A. A. (2017). The
Burden of Atopic Dermatitis: Summary of a Report for the National Eczema Association.
Journal of Investigative Dermatology, 137(1), 26–30.
https://doi.org/10.1016/j.jid.2016.07.012
Eczema (Atopic Dermatitis) | NIH: National Institute of Allergy and Infectious Diseases. (2018).
Retrieved October 16, 2018, from https://www.niaid.nih.gov/diseases-conditions/eczemaatopic-dermatitis
Ersser, S. j., Farasat, H., Jackson, K., Gardiner, E., Sheppard, Z. a., & Cowdell, F. (2015).
Parental self-efficacy and the management of childhood atopic eczema: development and

20

MANAGING CHILDHOOD ATOPIC DERMATITIS
testing of a new clinical outcome measure. British Journal of Dermatology, 173(6),
1479–1485. https://doi.org/10.1111/bjd.14175
Filanovsky, M. G., Pootongkam, S., Tamburro, J. E., Smith, M. C., Ganocy, S. J., & Nedorost, S.
T. (2016). The Financial and Emotional Impact of Atopic Dermatitis on
Children and Their Families. The Journal of Pediatrics, 169, 284-290.e5.
https://doi.org/10.1016/j.jpeds.2015.10.077
Francis, N. A., Ridd, M. J., Thomas-Jones, E., Butler, C. C., Hood, K., Shepherd, V., … Sullivan,
F. (2017). Oral and Topical Antibiotics for Clinically Infected Eczema in Children: A
Pragmatic Randomized Controlled Trial in Ambulatory Care. Annals of Family Medicine,
15(2), 124–130. https://doi.org/10.1370/afm.2038
Ghani, A. A. A., Noor, N. M., Muhamad, R., & Ismail, Z. (2013). Atopic Eczema in Children:
Disease Severity, Quality of Life and Its Impact on Family. International Medical
Journal, 20(3), 320–322.
Gilliam, A. E., Madden, N., Sendowski, M., Mioduszewski, M., & Duderstadt, K. (2016). Use of
Eczema Action Plans (EAPs) to improve parental understanding of treatment regimens in
pediatric atopic dermatitis (AD): A randomized controlled trial. Journal of the American
Academy of Dermatology, 74(2), 375–377.
How Much Does Eczema Treatment Cost? - CostHelper.com. (2018). Retrieved April 24, 2018,
from http://health.costhelper.com/eczema.html
How will I know what to do to control the eczema? (2018). Retrieved March 8, 2018, from
https://www.aad.org/public/diseases/eczema/eczema-resource-center/controllingeczema/eczema-action-plan

21

MANAGING CHILDHOOD ATOPIC DERMATITIS
Innes-Leroux, E. (2016, November 24). Atopic dermatitis action plan has potential to improve
outcomes in pediatric cases. Retrieved March 8, 2018, from http://www.derm.city/singlepost/2016/11/24/Atopic-dermatitis-action-plan-has-potential-to-improve-outcomes-inpediatric-cases
Lee, H., Son, H., Kim, J., Han, M., & Noh, G. (2016). Reliability and Validity of the KoreanParental Self-Efficacy with Eczema Care Index. Global Journal of Health Science, 8(10),
p57. https://doi.org/10.5539/gjhs.v8n10p57
Levy, M. L. (2013). Failing to Clarify Treatment Action Plans With Mom in Pediatric Atopic
Dermatitis: Comment on “Maternal Adherence Factors in the Treatment of Pediatric
Atopic Dermatitis.” JAMA Dermatology, 149(2), 231–231.
https://doi.org/10.1001/jamadermatol.2013.2411
Patient Handouts. (2018). Retrieved March 8, 2018, from http://pedsderm.net/for-patientsfamilies/patient-handouts/
Powell, K., Roux, E. L., Banks, J. P., & Ridd, M. J. (2018). Developing a written action plan for
children with eczema: a qualitative study. Br J Gen Pract, 68(667), e81–e89.
https://doi.org/10.3399/bjgp17X693617
Santer, M., Burgess, H., Yardley, L., Ersser, S. J., Lewis-Jones, S., Muller, I., … Little, P. (2013).
Managing childhood eczema: qualitative study exploring carers’ experiences of barriers
and facilitators to treatment adherence. Journal of Advanced Nursing, 69(11), 2493–2501.
https://doi.org/10.1111/jan.12133
Sauder, M. B., McEvoy, A., & Ramien, M. L. (2016). Prescribing success: Developing an
integrated prescription and eczema action plan for atopic dermatitis. Journal of the

22

MANAGING CHILDHOOD ATOPIC DERMATITIS
American Academy of Dermatology, 75(6), 1281–1283.
https://doi.org/10.1016/j.jaad.2016.08.029
Shaw, T. E., Currie, G. P., Koudelka, C. W., & Simpson, E. L. (2011). Eczema Prevalence in the
United States: Data from the 2003 National Survey of Children’s Health. Journal of
Investigative Dermatology, 131(1), 67–73. https://doi.org/10.1038/jid.2010.251
Shi, V., Shivani, N., Lee, K., Armstrong, A., & Lio, P. (2013). Improving Patient Education With
an Eczema Actin Plan: A Randomized Controlled Trial. JAMA Dermatology, 149(4),
481–483.
Sidbury, T., Bergman, J., Copper, K., Silverman, R., & Berger, T. (2014). Guidelines of care for
the management of atopic dermatitis: Section 4. Prevention of disease flares and use of
adjunctive therapies and approaches. Journal of the American Academy of Dermatology,
71(6), 1218–1233.
Silverberg, J., & Simpson, E. L. (2014). Associations of childhood eczema severity: A US
population based study. Dermatitis, 25(3), 107–114.
Tollefson, M. M., Bruckner, A. L., & Dermatology, S. O. (2014). Atopic Dermatitis: SkinDirected Management. Pediatrics, 134(6), e1735–e1744.
https://doi.org/10.1542/peds.2014-2812
Waldecker, A., Malpass, A., King, A., & Ridd, M. J. (2013). Written action plans for children
with long-term conditions: A systematic review and synthesis of qualitative data. Health
Expectations, n/a-n/a. https://doi.org/10.1111/hex.12643

23

MANAGING CHILDHOOD ATOPIC DERMATITIS
Table 1
Caregiver Type
Type

Frequency

%

Mother
Father
Grandparent
Sibling
Aunt

19
8
1
1
1

64%
27%
3%
3%
3%
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Table 2
Age of Caregiver
Age in years

Frequency

%

18-25

2

7%

26-35

21

70%

36-45

4

13%

46-65

3

10%
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Table 3
Primary Language of Caregiver
Primary language

Frequency

%

English
Vietnamese
Spanish
Azari
Lao
Somali

13
8
6
1
1
1

44%
27%
20%
3%
3%
3%
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Table 4
Work Status of Caregivers
Work status

Frequency

%

Full-time
Part-time
Does not work

18
1
11

60%
3%
37%
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Table 5
Age of Children
Age

Frequency

%

<6 months
≥6 months-24 months
>2-5 years
6-10 years
11-15 years
16-18 years

5
10
9
2
3
1

17%
33%
30%
7%
10%
3%
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Table 6
Child Gender
Sex of child

Percentage of sample

Male
Female

50%
50%
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Table 7
Race of Children
Race

Frequency

Approximate %

White

1

3%

Hispanic

16

53%

Asian
Black
Asian Hispanic

7
2
1

23%
7%
3%

White Hispanic
Prefer not to answer

1
1

3%
3%

30

MANAGING CHILDHOOD ATOPIC DERMATITIS
Table 8
Child Allergy, Medical History, Exposure
Type

Frequency

%

Seasonal allergy
(family history)
Food allergy (family history)
Food allergy
Asthma
Asthma (family history)
Smokers in the home

10

33%

4
4
2
6
5

13%
13%
7%
20%
17%
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Table 9
Duration of Eczema Prior to EAP
Time

Frequency

%

<6 months
6-12 months
>12 months

12
6
12

40%
20%
40%
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Table 10
History of Eczema Action Plan
Type

Frequency

%

History of using EAP
No history of using EAP

3
27

10%
90%
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Average Eczema Severity Scores
8.00

7.33

7.00

POEM Scores

6.00
5.00
4.00
2.55

3.00
2.00
1.00
0.00

PRE-EAP

POST-EAP

Figure 1: Eczema severity decreased by 4.78 average POEM points post EAP. This illustrates a
reduction in eczema severity.
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Figure 2: Eczema severity ranged from clear to very severe pre-EAP and improved to clear to
mild post-EAP. This illustrates a reduction in eczema severity.
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Figure 3: More than half of caregivers reported a decrease in eczema symptoms and nearly half
reported symptoms remained unchanged post EAP.
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Figure 4: Parental self-efficacy increased by an average of 2.6 PASECI points post-EAP. This
illustrates caregivers’ improvement in confidence in eczema management.
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Figure 5: Caregiver self-efficacy improved in all measured categories post-EAP.
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Appendix A
Demographics Questionnaire
Demographics Questionnaire
To be completed by parent/caregiver
Please circle your answer
1. Are you the caregiver of this child?

Yes

No

2. Who is filling out this form?

Parent

Grandparent

Relative

Guardian

26-35 years

36-45 years

3. What is your age?

Less than 18 years

18-25 years

46-65 years

4. Is English your primary language?

Yes

No

If No, what is your primary language? ____________________

5. Do you work or attend school:

Full-time

Part-time

Not currently working or attending school

6. What is the age of the child with eczema?

__________________________
7. What is the sex of the child?

Male

Female
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8. What is the race of the child?

White

Black

Hispanic

Asian
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Other
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Appendix A (continued)

Prefer not to answer
9. Does the child have asthma?

Yes

No

10. Does the child have food allergies?

Yes

No

If Yes, what foods?________________________________________________
11. Is there any family history of:

asthma

food allergies

seasonal allergies

none

12. Are there any smokers in the home where the child lives?

Yes

No

13. How long has your child had eczema?

Less than 6 months

6-12 months

more than a year

14. Have you ever received an Eczema Action Plan before?

Yes

No
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Appendix B
Patient-Oriented Eczema Measure for Children

POEM (Patient-Oriented Eczema Measure)- for proxy completion by caregiver
Please circle one response for each of the seven questions below about your child’s eczema. If
your child is old enough to understand the question then please fill in the questionnaire
together. Please leave blank any questions you feel unable to answer.

1. Over the last week, on how many days has your child’s skin been itchy because of their
eczema?

No days

1-2 days

3-4 days

5-6 days

Every day

2. Over the last week, on how many nights has your child’s sleep been disturbed because of
their eczema?

No days

1-2 days

3-4 days

5-6 days

Every day

3. Over the last week, on how many days has your child’s skin been bleeding because of their
eczema?

No days

1-2 days

3-4 days

5-6 days

Every day

4. Over the last week, on how many days has your child’s skin been weeping or oozing clear
fluid because of their eczema?

No days

1-2 days

3-4 days

5-6 days

Every day

5. Over the last week, on how many days has your child’s skin been cracked because of their
eczema?
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No days

1-2 days

3-4 days

5-6 days

Every day

6. Over the last week, on how many days has your child’s skin been flaking off because of their
eczema?

No days

1-2 days

3-4 days

5-6 days

Every day

7. Over the last week, on how many days has your child’s skin felt dry or rough because of their
eczema?

No days

1-2 days

3-4 days

5-6 days
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Appendix C
Parental Self-Efficacy with Eczema Care Index

MANAGING MEDICATION/ECZEMA AND SYMPTOMS: How CONFIDENT do you feel that you can:

1. Choose a moisturizer (grease) that is suitable for your child _____
0
1
Cannot do

2

3

4

5

6

7

8
9
10
Highly certain can do

2. Successfully apply moisturizers (grease) to your child’s eczema _____
0
1
Cannot do

2

3

4

5

6

7

8
9
10
Highly certain can do

6

7

8
9
10
Highly certain can do

3. Correctly use steroid creams for your child _____
0
1
Cannot do

2

3

4

5

4. Make the right choice of medication if the symptoms of your child’s eczema become worse _____
0
1
Cannot do

2

3

4

5

6

7

8
9
10
Highly certain can do

5. Manage to avoid things that irritate/aggravate your child’s eczema _____
0
1
Cannot do

2

3

4

5

6

7

8
9
10
Highly certain can do

6. Manage your child’s eczema so that his/her symptoms are under control _____
0
1
Cannot do

2

3

4

5

6

7

8
9
10
Highly certain can do

7. Know what to do if you think your child’s eczema has become infected _____
0

1

2

3

4

5

6

Cannot do

7

8

9

10

Highly certain can do
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Appendix D
American Academy of Dermatology Eczema Action Plan
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Appendix E
Pediatric Society of Dermatology Patient Education Handout
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Appendix F
National Eczema Association Endorsed Over-the-Counter Products

How products qualify for the
NEA Seal of Acceptance™

Manufacturers submit product ingredient information, formulation data, and testing results (sensitivity,
safety and toxicity) for scientific review by the National Eczema Association. Products eligible for the
NEA Seal of Acceptance™ are those that have been
created or intended for use by people with eczema
or sensitive skin. The Seal of Acceptance Review
Panel consists of experts in dermatology, allergy and
pediatrics.
The NEA Seal of Acceptance™ program evaluates
products in the following categories:
l Personal Care Products
l OTC Drugs
l Household Products
l Fabric Products

The NEA Seal of Acceptance™
Product Directory

The Product Directory contains a listing of products
that have received the NEA Seal of Acceptance™.
Further information about Seal of Acceptance
products can be found on the NEA website.

Personal Care Products

The importance of proper bathing and moisturizing
practices cannot be over-emphasized as a treatment
for eczema and sensitive skin. Use of mild, fragrance
free, low-pH cleansers are best. Moisturizers maintain
skin hydration and barrier function. Generic petroleum
jelly and mineral oil (without additives) are two of
the most effective moisturizing products.
MOISTURIZERS
l AVEENO®

Baby Eczema Therapy Moisturizing Cream
Baby Eczema Therapy Soothing Bath Treatment
AVEENO® Eczema Therapy Bath Treatment
AVEENO® Eczema Therapy Moisturizing Cream
Avène TriXéra+ Selectiose® Emollient Cream
Baby Pibu™ Baby Butter
Baby Pibu™ Hydrating Ointment
BabySpa® Natural Relief Eczema Cream
CapriClear®
CeraVe® Moisturizing Cream
CeraVe® Moisturizing Lotion
CeraVe® Renewing SA Cream
CeraVe® SA Renewing Lotion
CeraVe® SA Therapeutic Hand Cream
Cetaphil® RESTORADERM® Skin Restoring Moisturizer
Curél® Itch Defense® Lotion
Dove® DermaSeries Extreme Dryness Relief Intense Repairing
Rough Patch Treatment

l AVEENO®
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l

Dove® DermaSeries Extreme Dryness Relief Intense Repairing
Body Eczema Therapy Cream
Dove® DermaSeries Extreme Dryness Relief Intense Repairing
Body Cream
l Exederm™ Baby Lotion
l Exederm™ Baby Moisturizer
l Exederm™ Baby Oil
l Exederm™ Body Lotion
l Exederm™ Body Oil
l Exederm™ Intensive Moisture Cream
l Hydrolatum®
l Glaxal Base® Everyday Moisturizing Lotion
l Glaxal Base® Moisturizing Cream
l Gold Bond® Ultimate Eczema Relief Lotion
l MD Moms® Baby Silk Daily Skin Protection Moisturizing Balm
l MD Moms® Baby Silk Daily Skin Protection Moisturizing Balm
— unfragranced
l MD Moms® Baby Silk Dry Skin Rescue Extreme Care Cream
— unfragranced
l Mustela® Dermo-Pediatrics Stelatopia® Lipid-Replenishing Balm
l Mustela® Dermo-Pediatrics Stelatopia® Milky Bath Oil
l Mustela® Dermo-Pediatrics Stelatopia® Moisturizing Cream
l NEOSPORIN® ECZEMA ESSENTIALS™ Daily Moisturizing Cream
l Neutrogena® Norwegian Formula® Hand Cream
l Neutrogena® Oil-Free Moisture for Sensitive Skin
l Remarle® Shea Butter Crème
l Theraplex® ClearLotion®
l Theraplex® Eczema Therapy
l Theraplex® Emollient
l Triple Cream®
l Vaseline® 100% Pure Petroleum Jelly
l Vanicream™ Lite Lotion
l Vanicream™ Skin Cream
l Vaniply™ Ointment
l Weleda White Mallow Face Cream
l Weleda White Mallow Body Lotion
l
l

CLEANSERS

Albolene® Moisturizing Cleanser
AVEENO® Baby Cleansing Therapy Moisturizing Wash
Avène TriXéra+ Selectiose® Emollient Cleansing Gel
l Avène TriXéra+ Selectiose® Emollient Cleansing Bath
l Baby Pibu™ Bathtime Wash
l CeraVe® Hydrating Cleanser
l Cetaphil® RESTORADERM® Skin Restoring Body Wash
l CLn® BodyWash
l CLn® Facial Cleanser
l CLn® SportWash
l Dove® DermaSeries Extreme Dryness Relief Ultra Caring
Gentle Body Cleanser
l Dove® DermaSeries Extreme Dryness Relief Ultra Caring
Gentle Cream Face Cleanser
l Dove® DermaSeries Extreme Dryness Relief Ultra Caring
Gentle Cleansing Bar
l Exederm™ Baby Bath

l
l
l
l
l
l
l
l
l

Exederm™ Body Wash
Kiss of Nature Oh My Baby!! Fragrance Free Moisturizing Body Bar
Kiss of Nature Oh My Sassy Baby!! Fragrance Free
Moisturizing Body Bar with Goat Milk
Kiss of Nature Oh My Baby!! Fragrance Free Liquid Castile
Hand Soap
MD Moms® Baby Silk Gentle All-Over Cleansing Towelettes
— unfragranced
MD Moms® Baby Silk Gentle All-Over Cleansing Towelettes
Mustela® Dermo-Pediatrics Stelatopia® Cream Cleanser
NEOSPORIN® MOISTURE ESSENTIALS™ Daily Body Wash
Neutrogena® Ultra Gentle Hydrating Cleanser

HAIR PRODUCTS
l

Exederm™ Baby Shampoo

l MD Moms® Baby Silk Gentle All-Over Clean Hair & Body Wash
l MD Moms® Baby Silk Gentle All-Over Clean Hair & Body Wash

- unfragranced
Conditioner
Shampoo

l Exederm™

l Exederm™

OTC Drugs

Over-the-counter (OTC) medicines are drugs you
can buy without a prescription. It is important to
take medicines correctly, and be careful when giving
them to children. More medicine does not necessarily
mean better. You should never take OTC medicines
longer or in higher doses than the label recommends.
If your symptoms don’t go away, it’s a clear signal
that it’s time to see your healthcare provider.
OTC drugs containing hydrocortisone require
special care.
l Cortizone-10® Hydratensive™ Eczema Lotion
l Cortizone-10® Intensive Healing Lotion Eczema
l Exederm™ Flare Control Cream
l NEOSPORIN® ECZEMA ESSENTIALS™
Hydrocortisone Anti-Itch Cream

l

l
l

Household Products

Products accepted by NEA avoid certain chemicals,
dyes, perfumes, and residues that can irritate eczema
and sensitive skin.
l `all® FREE CLEAR Laundry Detergent

Fabric Products

Certain clothing, linens, and other fabric products can
be beneficial for those with eczema or sensitive skin.
l AD RescueWear wet wrap therapy garments
l DermaTherapy® Pillow Cases
l DermaTherapy® Sheets
l HALO® ComfortLuxe™ Sensitive Skin Sleepwear

nationaleczema.org
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Appendix G
Caregiver’s Comprehension of Eczema Action Plan
1. How well do you understand your child’s Eczema Action Plan? Circle a number.

0

1

2

3

4

5

6

No understanding

7

8

9

10

full understanding
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Appendix H
Participant Contact Information and Offer for Incentive Form

1ST ENCOUNTER
USD COPY
RETURN FORMS BY
__________________

Date:
Dear Parent/Caregiver,

Thank you for participating in this important pilot project to manage childhood eczema. I
would like to find out how well the Eczema Action Plan works for you and your child in 6 weeks.
Please indicate how you would like to return 2 forms:
• POEM (Patient-Oriented Eczema Measure)
• Parental Self-Efficacy with Eczema Care Index
Take a picture of the forms and text to (XXX) XXX-XXXX.

Phone call. Best time to call________________________________________________

Please e-mail forms to XXXXXXXXXXXXXXX.
As an appreciation for your participation, I would like to offer you a $20 gift card to Walmart at
the completion of the study. Please provide your contact information which will remain private
and will not be shared.
Parent/Caregiver Name___________________________________________________________
Address_______________________________________________________________________
Phone number__________________________________________________________________
E-mail address__________________________________________________________________

Thank you,

Tiffany Sena, BSN, RN, Doctor of Nursing Practice Candidate
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